Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07489521
PHASE4

Arthrosemid vs. Steroid for the Management Knee Osteoarthritis

Sponsor: Cappagh National Orthopaedic Hospital

View on ClinicalTrials.gov

Summary

This study will be a randomised control trial of the use of intra-articular Arthrosamid® a novel intraarticular hydrogel vs. standard of care (steroid and local anaesthetic) for the non-operative management of knee osteoarthritis.

Official title: A Randomised Control Trial of the Use of an Intraarticular Hydrogel Arthrosemid® vs. Steroid for the Non-operative Management of Moderate to Severe Osteoarthritis

Key Details

Gender

All

Age Range

18 Years - 100 Years

Study Type

INTERVENTIONAL

Enrollment

200

Start Date

2026-03

Completion Date

2027-09

Last Updated

2026-03-27

Healthy Volunteers

Yes

Interventions

DEVICE

Arthrosamid® 2.5% iPAAG injectable implant

Arthrosamid is a non-biodegradable, 2.5% polyacrylamide hydrogel (iPAAG) injection designed as a long-lasting, non-surgical treatment for knee osteoarthritis. It acts as a synovial implant that provides cushioning, reduces pain, and improves mobility for up to 3-4 years, often delaying the need for knee replacement surgery.

DRUG

Steroid Drug

dexamethasone 8mg, methylprednisolone 80mg and bupivacaine 5ml 0.25%, intra articular injection

Locations (1)

Cappagh National Orthopaedic Hospital

Dublin, Dublin, Ireland